Man-made blood vessels developed by researchers at Duke University, Yale University and the tissue engineering company Humacyte appear to be both safe and more durable than commonly used synthetic versions in patients undergoing kidney dialysis, the researchers report.
The findings, published May 12 in The Lancet, resulted from a phase 2 study among 60 patients with kidney failure who required dialysis, which often requires a synthetic graft when the patient’s own blood vessel degrades from frequent needle sticks.
Such grafts, however, are prone to infection, clotting, and other complications. And alternative bioengineered grafts derived from the patient, a donor, or animal tissue have been shown to perform no better than synthetics.
The Duke and Yale research team — along with surgeons in Poland and the United States and scientists at Humacyte, which is developing the bioengineered vessel — tested a human acellular vessel, or HAV, that is manufactured to be available to patients on demand, rather than made-to-order using an individual’s own cells.
“The bioengineered blood vessel represents a critical step in tissue engineering,” said Jeffrey Lawson, M.D., Ph.D., professor of surgery and pathology at Duke and chief medical officer of Humacyte. “Because these vessels contain no living cells, patients have access to off-the-shelf engineered grafts that can be used without any waiting period associated with tailor-made products.”
Lawson and co-author Laura Niklason, M.D., Ph.D., professor of anesthesiology and biomedical engineering at Yale, are principals of Humacyte, Inc., which supported the clinical trial.
To create the vessels, the researchers first isolated vascular cells from human donors and grew them in tissue culture. They then placed the cells on a degradable scaffold shaped like a blood vessel. As the tissue grew, it was bathed in nutrients and stretched to acquire the physical properties of real blood vessels.
“After that process, which takes eight weeks, the scaffold degrades and what we have left is engineered tissue that we have grown from scratch,” Niklason said.
The final step was to wash away the cells with a special solution. The remaining “de-cellularized” tissue retains the structure of the vessel but none of the components that would cause tissue rejection.
One year after implantation, the bioengineered vessels appeared to be both safe and functional, maintaining their mechanical integrity, the researchers report. The patients also showed no sign of rejection.
While there were cases of adverse events such as clotting, the rates of those events were comparable to other dialysis grafts. Notably, the durability of the bioengineered vessels at one year was 89 percent, compared to the approximately 60-percent rate of synthetic grafts reported in previous studies.
Additionally, the researchers noted that after implantation, the bioengineered vessels had been repopulated with the patient’s own cells, so nonliving tissue became living over time.
“The fact that an implanted acellular tube becomes a living human tissue has implications for regenerative medicine in a very profound way,” Lawson said.
The Latest on: Bioengineered Blood Vessel
via Google News
The Latest on: Bioengineered Blood Vessel
- Bioengineered vessels transform into living blood vessels on April 9, 2019 at 10:24 am
Bioengineered vessels that were implanted in people to aid with kidney dialysis matured into living blood vessels. The 4-year study demonstrates that the vessels, called human acellular vessels, can ... […]
- Artificial blood vessels that come to life could improve medical care. Here's why. on April 9, 2019 at 1:40 am
Fake blood vessels are starting to get real. New research shows that “bioengineered” blood vessels are able to incorporate living cells after being implanted in the human body, becoming blood-carrying ... […]
- Bioengineered blood vessels may help vascular disease patients on April 8, 2019 at 11:18 pm
Researchers at Yale and North Carolina-based biotechnology and regenerative medicine company Humacyte have confirmed that their bioengineered blood vessels evolve into living tissue in patients, ... […]
- Humacyte Awarded ‘Large Project Prototype of the Year’ from The Medical Technology Enterprise Consortium on April 8, 2019 at 8:00 am
Humacyte’s HAV, HUMACYL ®, is an investigational, off-the-shelf bioengineered blood vessel that is being studied for use in the repair and reconstruction of vascular injuries from violent civilian or ... […]
- Bioengineered Blood Vessels Replace Damaged Vessels in Patients on March 28, 2019 at 7:56 pm
In 60 patients with end-stage kidney failure over a four-year phase 2 clinical trial, the bioengineered blood vessels were safely and effectively integrated into the native circulatory systems. Blood ... […]
- Lab-grown blood vessels could be big medical advance on March 28, 2019 at 4:23 pm
Blood vessels created in the lab can successfully ... involved in the study called the progress being made toward bioengineered vessels "exciting." "Having a vessel that handles and acts like ... […]
- Long term study finds engineered blood vessels turned to living tissue on March 28, 2019 at 6:01 am
Researchers from Yale and a medical company called Humacyte have published the results of a long term study that shows engineered blood vessels that are implanted into humans eventually evolved into ... […]
- Lab-grown blood vessels could make dialysis easier on March 27, 2019 at 5:16 pm
Now, researchers from Humacyte Inc., Duke University and Yale think they're one step closer to using bioengineered blood vessels. These would replace synthetic polymers and donor tissues, which carry ... […]
- Blood vessels built from a patient’s cells could help people on dialysis on March 27, 2019 at 11:41 am
Bioengineered blood vessels are one step closer to being available for patients. In clinical trials, these vessels were installed in the arms of dialysis patients and successfully integrated into ... […]
- Self-sustaining, bioengineered blood vessels could replace damaged vessels in patients on March 27, 2019 at 11:12 am
A research team has bioengineered blood vessels that safely and effectively integrated into the native circulatory systems of 60 patients with end-stage kidney failure over a four-year phase 2 ... […]
via Bing News